Javad Amini Mahabadi | Health Sciences | Editorial Board Member

Dr. Javad Amini Mahabadi | Health Sciences | Editorial Board Member

Anatomical and Gametogenesis Research Center | Iran

Dr. Javad Amini Mahabadi is an accomplished Iranian researcher in reproductive biology, stem cell science, and assisted reproductive technologies, affiliated with the Gametogenesis Sciences Research Center and the Anatomical Sciences Research Center at Kashan University of Medical Sciences, as well as the Sarem Gynecology, Obstetrics and Infertility Research Center and the Sarem Cell Research Center in Tehran. Born on 22 March 1985 in Ardestan, Isfahan, he holds a Ph.D. in Reproductive Biology from Kashan University of Medical Sciences, an M.Sc. in Animal Physiology from the University of Zanjan, and a B.Sc. in Animal Science from Razi University. His research interests span reproductive biology, IVF and ICSI, stem cells, medical genetics, histopathology, physiology, and animal science. Dr. Amini Mahabadi has an impressive scientific footprint with h-index 12 in Google Scholar and 9 in Scopus, reflecting influential contributions in male fertility, germ cell differentiation, embryonic development, nanofiber-based stem cell engineering, and the protective effects of natural compounds on reproductive tissues. He has authored and co-authored more than 20 international journal papers in highly regarded outlets such as Andrologia, Journal of Cellular Biochemistry, Cytotherapy, Journal of Cellular Physiology, Theriogenology, and Gene, as well as several internal journal publications. His scholarly works include pioneering studies on the differentiation of induced pluripotent stem cells into male and female germ cell lineages, microRNA roles in stem cell biology, reproductive toxicity, and therapeutic approaches using natural extracts and biomaterials. With extensive experience in laboratory animal handling, histological and molecular techniques, MEF and iPSC culture, IVF/ICSI procedures, and embryology, he is also well-versed in advanced assays including flow cytometry, real-time PCR, Western blotting, immunocytochemistry, and micromanipulation. Dr. Amini Mahabadi has supervised numerous research projects and actively served as a referee for journals such as the Iranian Journal of Basic Medical Sciences and Pharmaceutical Biology. He has taught at university level, delivered workshops on stem cell culture, sperm analysis, scientific writing, and research methodology, and contributed significantly to the student research committee at KAUMS. His professional training includes specialized courses in stem cell culture at Bonyakhteh Center, IVF and ICSI at Kashan Beheshti Hospital, and ART techniques at Sarem Women’s Hospital. Supported by a strong network of academic referees, Dr. Amini Mahabadi continues to advance reproductive science through rigorous research, clinical collaboration, and scientific mentorship.

Profile: Scopus | Orcid

Featured Publications

Amini Mahabadi, J., Enderami, S. E., Nikzad, H., Hassani Bafrani, H., & Sanchez, R. (2024).
The use of machine learning for human sperm and oocyte selection and success rate in IVF methods. Andrologia. https://doi.org/10.1155/and/8165541

Giti, S., Amini Mahabadi, J., & Nateghi, M. R. (2022).
A case report of papyrus fetus. Sarem Journal of Medical Research, 7(1), 25. https://doi.org/10.61186/sjrm.7.1.25

Nateghi, M. R., & Amini Mahabadi, J. (2022).
Investigating the expression of mesenchymal stem cell markers in human bone marrow stem cells. Sarem Journal of Medical Research, 7(3), 165. https://doi.org/10.61186/sjrm.7.3.165

Abazari, M. F., Soleimanifar, F., Amini Faskhodi, M., Mansour, R. N., Amini Mahabadi, J., Sadeghi, S., Hassannia, H., Saburi, E., Enderami, S. E., Khani, M. M., et al. (2020).
Improved osteogenic differentiation of human induced pluripotent stem cells cultured on polyvinylidene fluoride/collagen/platelet-rich plasma composite nanofibers. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.29029

Shafiei, G., Almasi, M., Nikzad, H., Miyan, J., Mahabadi, J. A., & Moshkdanian, G. (2020).
L-carnitine reduces the adverse effects of ROS and up-regulates the expression of implantation-related genes in in vitro developed mouse embryos. Theriogenology. https://doi.org/10.1016/j.theriogenology.2020.01.008

Tahmasebi, A., Enderami, S. E., Saburi, E., Islami, M., Yaslianifard, S., Mahabadi, J. A., Ardeshirylajimi, A., Soleimanifar, F., & Moghadam, A. S. (2020).
Micro-RNA-incorporated electrospun nanofibers improve osteogenic differentiation of human-induced pluripotent stem cells. Journal of Biomedical Materials Research: Part A. https://doi.org/10.1002/jbm.a.36824

Amini Mahabadi, J., Karimian, M., Aghighi, F., Enderami, S. E., Seyyed Hosseini, E., Talaei, S. A., Gheibi Hayat, S. M., & Nikzad, H. (2020).
Retinoic acid and 17β-estradiol improve male germ cell differentiation from mouse-induced pluripotent stem cells. Andrologia. https://doi.org/10.1111/and.13466

EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Dr. EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Clinical pharmacy resident at Tehran University of Medical Sciences, Iran.

Dr. Emad Molaei is a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences/Imam Khomeini Hospital Complex. With a PharmD from Mashhad University of Medical Sciences and a current residency in Pharmacotherapy, he has a strong foundation in clinical pharmacy. His research focuses on nephroprotective activity, cardiovascular diseases, and COVID-19 treatments, with several first-author publications in renowned journals. Dr. Molaei’s professional experience includes roles as a community pharmacist, medication consultant, and pharmacotherapy interventionist in various hospitals. He is also the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company. Recognized for his academic excellence, he has received multiple awards and honors, including being the top-ranked graduate and outstanding student at each academic level. Dr. Molaei is skilled in data analysis, scientific writing, and project management, contributing significantly to his field.

Professional Profiles:

Education 🎓

🎓 Emad Molaei is currently pursuing his Pharmacotherapy (Clinical Pharmacy) residency at the School of Pharmacy, Tehran University of Medical Sciences (TUMS), since September 2021. He completed his Pharm-D at the School of Pharmacy, Mashhad University of Medical Sciences (MUMS) in September 2021, achieving a commendable total average of 18.00. Prior to that, he earned his Diploma of Science from the Gifted Program in the National Organization for Development, with an impressive total average of 19.46 in September 2015.

Professional Experience

👨‍⚕️ Emad Molaei’s professional journey includes his current role as a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences / Imam Khomeini Hospital Complex. He has extensive clinical experience as a Community Pharmacist at 13-Aban TUMS Community Chain Pharmacy in Tehran and Razavi Pharmaceutical Service Institute in Mashhad. Additionally, he has served as a Medication Consultant at the Drug and Poison Information Center (DPIC) in Tehran and has been involved in pharmacotherapy interventions at several hospitals, including Imam Khomeini, Shariati, Sina, and Roozbeh Hospitals in Tehran. Emad also has experience working in the satellite pharmacy of the critical care department at Sina Hospital and initiated activities in the clean room dedicated to cytotoxic drug production at the Cancer Institute, Imam Khomeini Hospital Complex. Beyond his clinical roles, he has contributed as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology.

Research Interest

🔬 Emad Molaei’s research interests span across various aspects of clinical pharmacy and pharmacotherapy. He is particularly focused on the nephroprotective activity of natural products against chemical toxicants and the role of the Nrf2/ARE signaling pathway. Emad also investigates the therapeutic potential of Resolvin D1 in Acute Respiratory Distress Syndrome and explores emerging therapeutic targets for cardiovascular diseases, including the LKB1 pathway and the Mas receptor. Additionally, he is involved in clinical studies evaluating the efficacy and safety of treatments for burn patients, such as silver sulfadiazine 1%-cerium nitrate 2.2% cream. Emad’s work also extends to the treatment of COVID-19 with Remdesivir in special populations, showcasing his commitment to addressing critical health issues through innovative research.

Award and Honors

🏆 Emad Molaei has received numerous awards and honors throughout his academic and professional career. He was recognized as the most outstanding student at each academic level and graduated as the top-ranked student from the Mashhad Faculty of Pharmacy. Emad also achieved the highest rank in the pharmacy specialty examination and is a member of the Brilliant Academic Talent Program. His presentation skills have been acknowledged with the best poster award at the 12th subspecialty congress of Iranian burn physicians. Emad’s dedication to excellence is further demonstrated by his active membership in various professional organizations and his role as the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company.

Research Skills

🧪 Emad Molaei possesses a robust set of research skills. He is proficient in data analysis using software such as SPSS, GraphPad Prism, and Sigma Plot. His scientific writing abilities are well-honed, and he is adept with EndNote and Microsoft Office tools. Emad’s project management skills are complemented by his experience as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology. His clinical research experience includes participation in multiple clinical trials and studies, showcasing his ability to handle complex research projects effectively.

Publications by Emad Molaei

  1. Remdesivir: Treatment of COVID-19 in Special Populations
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • Year: 2024
    • Citations: 1
  2. Mas Receptor: A Potential Strategy in the Management of Ischemic Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Hayes, A.W., Karimi, G.
    • Journal: Cell Cycle
    • Year: 2023
    • Citations: 5
  3. LKB1: An Emerging Therapeutic Target for Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Sadeghnia, H., Hayes, A.W., Karimi, G.
    • Journal: Life Sciences
    • Year: 2022
    • Citations: 13
  4. Resolvin D1: Therapeutic Target in Acute Respiratory Distress Syndrome
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: European Journal of Pharmacology
    • Year: 2021
    • Citations: 18
  5. Nephroprotective Activity of Natural Products Against Chemical Toxicants: The Role of Nrf2/ARE Signaling Pathway
    • Authors: Molaei, E., Molaei, A., Abedi, F., Hayes, A.W., Karimi, G.
    • Journal: Food Science and Nutrition
    • Year: 2021
    • Citations: 23